Regeneron Pharmaceuticals (REGN) Invested Capital (2009 - 2026)

Regeneron Pharmaceuticals' Invested Capital history runs 18 years deep, the most recent figure standing at $31.4 billion for Q1 2026.

• In Q1 2026, Invested Capital rose 6.93% year-over-year to $31.4 billion; the TTM figure through Mar 2026 stood at $31.4 billion (up 6.93% YoY), while the FY2025 annual figure was $32.0 billion, up 2.04% from the prior year.
• Invested Capital was $31.4 billion for Q1 2026 at Regeneron Pharmaceuticals, down from $32.0 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $32.0 billion in Q4 2025 to a low of $20.7 billion in Q1 2022.
• Historically, Invested Capital has averaged $26.9 billion across 5 years, with a median of $27.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Invested Capital jumped 62.42% in 2022, then advanced 2.04% in 2025.
• A 5-year view of Invested Capital shows it stood at $23.4 billion in 2022, then increased by 14.14% to $26.7 billion in 2023, then gained by 17.31% to $31.3 billion in 2024, then increased by 2.04% to $32.0 billion in 2025, then decreased by 1.73% to $31.4 billion in 2026.
• The last three Invested Capital figures came in at $31.4 billion (Q1 2026), $32.0 billion (Q4 2025), and $31.0 billion (Q3 2025), per Business Quant data.